Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HAPC1573
- Development stage
- Preclinical
- Lead developer
- Bayer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
HAPC1573 is a murine monoclonal antibody (IgG1/κ) that selectively binds to human activated protein C (APC) and inhibits its anticoagulant activity without affecting its cytoprotective or anti-inflammatory functions. Originally developed at the Oklahoma Medical Research Foundation (OMRF), HAPC1573 serves as the parent antibody of SR604, a humanized monoclonal antibody being developed by Equilibra Bioscience and Shanghai RAAS for the treatment of hemophilia A, hemophilia B, and other bleeding disorders. By blocking the anticoagulant function of APC, HAPC1573 helps to rebalance the coagulation cascade, promoting thrombin generation and clot stability in factor-deficient environments.
02
Targets
PROC (Protein C)APC (Activated protein C)
Beyond the preview
Go deeper on HAPC1573.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAPC1573.